文献速递重症综合管理与镇静镇痛儿科与产科急症

电休克治疗中麻醉剂量减少的耐受性与临床结局

Tolerability and Clinical Outcomes With Anesthesia Dose Reduction During Electroconvulsive Therapy.
PubMed 文献 · JAMA Netw Open · 2025-02-03
一句话结论COVID-19期间电休克治疗减少麻醉剂量与球囊面罩通气使用减少相关,除初始镇静不足和发作后躁动增加外,临床结局和耐受性相似。

这项回顾性队列研究纳入2017年3月16日至2023年3月15日在加拿大成瘾与精神健康中心接受美索比妥和琥珀胆碱电休克治疗的患者616例,比较COVID-19前(362例)与COVID-19期间(254例)麻醉剂量减少与结局的关联。COVID-19组美索比妥和琥珀胆碱剂量均低于COVID-19前组,球囊面罩通气使用从标准使用降至13.8%(35例)。COVID-19组初始镇静剂量不足的比值比为2.16(95%CI 1.09-4.38),发作后躁动的比值比为2.81(95%CI 1.76-4.56),其他并发症无差异;两组应答率(68.0% vs 71.3%,P=.38)和认知损害率(20.7% vs 19.3%,P=.66)相似。作者认为该麻醉剂量策略下发作后躁动的管理值得进一步研究。

要点

  • COVID-19组美索比妥中位剂量0.82(0.72-0.96)mg/kg低于COVID-19前组0.87(0.78-1.00)mg/kg(P=.007),琥珀胆碱0.33(0.27-0.39)mg/kg低于0.53(0.45-0.59)mg/kg(P<.001)。
  • COVID-19期间球囊面罩通气使用从标准使用降至13.8%(35例)。
  • COVID-19组初始镇静剂量不足的比值比为2.16(95%CI 1.09-4.38),发作后躁动的比值比为2.81(95%CI 1.76-4.56),其他并发症无差异。
  • 两组应答率(COVID-19前246例[68.0%] vs COVID-19组181例[71.3%],P=.38)和认知损害率(75例[20.7%] vs 49例[19.3%],P=.66)相似。
  • 作者认为,该麻醉剂量策略下发作后躁动的管理值得进一步研究。

适用人群与场景

  • 2017年3月16日至2023年3月15日在加拿大成瘾与精神健康中心接受美索比妥和琥珀胆碱电休克治疗索引疗程的任何临床适应证患者。
  • 分为COVID-19前组(2017年3月至2020年3月治疗)和COVID-19组(2020年6月至2023年3月治疗)。
  • 共纳入616例,中位年龄45.0(31.0-59.0)岁,女性342例(55.5%);COVID-19前组362例,COVID-19组254例。

处置流程与药物剂量

  • COVID-19组接受美索比妥中位剂量0.82(0.72-0.96)mg/kg和琥珀胆碱中位剂量0.33(0.27-0.39)mg/kg,低于COVID-19前组美索比妥0.87(0.78-1.00)mg/kg和琥珀胆碱0.53(0.45-0.59)mg/kg。
  • COVID-19期间为减少球囊面罩通气,许多中心减少麻醉药物剂量;球囊面罩通气使用从标准使用降至13.8%(35例)。

研究设计与关键结果

  • 回顾性队列研究,纳入616例接受电休克治疗的患者,COVID-19前组362例,COVID-19组254例;COVID-19组美索比妥剂量0.82(0.72-0.96)mg/kg vs 0.87(0.78-1.00)mg/kg(P=.007),琥珀胆碱剂量0.33(0.27-0.39)mg/kg vs 0.53(0.45-0.59)mg/kg(P<.001)。
  • COVID-19组初始镇静剂量不足的比值比为2.16(95%CI 1.09-4.38),发作后躁动的比值比为2.81(95%CI 1.76-4.56),其他并发症无差异。
  • 球囊面罩通气使用从标准使用降至13.8%(35例)。
  • 两组应答率:COVID-19前组246例(68.0%) vs COVID-19组181例(71.3%),P=.38;认知损害率:COVID-19前组75例(20.7%) vs COVID-19组49例(19.3%),P=.66。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在电休克治疗中减少美索比妥和琥珀胆碱剂量与球囊面罩通气使用减少相关,临床结局和耐受性除初始镇静不足和发作后躁动增加外相似。
  • 作者认为,该麻醉剂量策略下发作后躁动的管理值得进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Electroconvulsive therapy (ECT) practice during the COVID-19 pandemic necessitated restriction of bag-valve mask (BVM) ventilation to minimize disease transmission through aerosolization. To reduce BVM use, many sites decreased doses of anesthesia agents, but the associations of such dose reduction with clinical and tolerability outcomes are unknown.

OBJECTIVES: To investigate the association of COVID-19 pandemic modifications in ECT, including reduction in anesthetic dosage and BVM use, with the rates of clinical complications and clinical outcomes.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included data from patients receiving an index course of ECT for any clinical indication treated with methohexital and succinylcholine between March 16, 2017, and March 15, 2023, at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada. Data analysis occurred from February to December 2024.

EXPOSURE: Participants were split into 2 cohorts: pre-COVID-19 (treated between March 2017 and March 2020) and COVID-19 (treated between June 2020 and March 2023).

MAIN OUTCOMES AND MEASURES: The primary outcomes were BVM use and rates of complications (specifically, aspiration, bradycardia, insufficient initial sedation dosage, postictal agitation [PIA], residual weakness, and prolonged seizures). Secondary outcomes were rates of response and cognitive impairment. Multivariable logistic regression was used to assess associations of COVID-19 pandemic modifications with outcomes.

RESULTS: A total of 616 individuals (median [IQR] age, 45.0 [31.0-59.0] years; 342 female [55.5%]) were included in the analysis, with 362 in the pre-COVID-19 group and 254 in the COVID-19 group. Demographic and clinical characteristics were similar. The COVID-19 group received lower median (IQR) methohexital dosages (0.82 [0.72-0.96] mg/kg vs 0.87 [0.78-1.00] mg/kg; P = .007) and succinylcholine (0.33 [0.27-0.39] mg/kg vs 0.53 [0.45-0.59] mg/kg; P < .001) than the pre-COVID-19 group. The COVID-19 group had higher odds of insufficient initial sedation dosage (odds ratio, 2.16, 95% CI, 1.09-4.38) and PIA (odds ratio, 2.81; 95% CI, 1.76-4.56), with no difference for other complications. BVM use was reduced from standard use to 13.8% (35 individuals) during COVID-19. Groups were similar in the rates of response (pre-COVID-19, 246 individuals [68.0%]; COVID-19, 181 individuals [71.3%]; P = .38) and cognitive impairment (pre-COVID-19, 75 individuals [20.7%]; COVID-19, 49 individuals [19.3%]; P = .66).

CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, reduction of anesthesia agents was associated with reduced BVM use, with similar clinical outcomes and tolerability other than increased rates of insufficient initial sedation dosage and PIA, suggesting that management of PIA with this anesthesia dosing strategy warrants further investigation.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Espinola CW, Kaster TS, Prillo J, et al. Tolerability and Clinical Outcomes With Anesthesia Dose Reduction During Electroconvulsive Therapy. JAMA Netw Open. 2025. PMID: 40014343. doi:10.1001/jamanetworkopen.2024.62054

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。